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Pathology findings of renal biopsy in LCCN predict renal outcomes independently of the
hematologic response.
In patients with MM and biopsy-proven LCCN, quality of renal response correlates with overall
survival.
Abstract
Light chain cast nephropathy (LCCN) in multiple myeloma often leads to severe and poorly reversible
acute kidney injury. Severe renal impairment influences the allocation of chemotherapy and its tolerability;
it also affects patient survival. Whether renal biopsy findings add to the clinical assessment in predicting
renal and patient outcomes in LCCN is uncertain. We retrospectively reviewed clinical presentation,
chemotherapy regimens, hematologic response, and renal and patient outcomes in 178 patients with
biopsy-proven LCCN from 10 centers in Europe and North America. A detailed pathology review,
including assessment of the extent of cast formation, was performed to study correlations with initial
presentation and outcomes. Patients presented with a mean estimated glomerular filtration rate (eGFR) of
13 ± 11 mL/min/1.73 m , and 82% had stage 3 acute kidney injury. The mean number of casts was
3.2/mm  in the cortex. Tubulointerstitial lesions were frequent: acute tubular injury (94%), tubulitis (82%),
tubular rupture (62%), giant cell reaction (60%), and cortical and medullary inflammation (95% and 75%,
respectively). Medullary inflammation, giant cell reaction, and the extent of cast formation correlated with
eGFR value at LCCN diagnosis. During a median follow-up of 22 months, mean eGFR increased to 43 ±
30 mL/min/1.73 m . Age, β -microglobulin, best hematologic response, number of cortical casts per
square millimeter, and degree of interstitial fibrosis/tubular atrophy (IFTA) were independently associated
with a higher eGFR during follow-up. This eGFR value correlated with overall survival, independently of
the hematologic response. This study shows that extent of cast formation and IFTA in LCCN predicts the
quality of renal response, which, in turn, is associated with overall survival.
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Learning objectives
Upon completion of this activity, participants will be able to:
1. Describe clinical and pathological features of light chain cast nephropathy (LCCN) in patients
with multiple myeloma (MM), according to a retrospective review
2. Determine the predictive value for outcomes of clinical and pathological features of LCCN in
patients with MM, according to a retrospective review
3. Identify clinical implications of the predictive value regarding outcomes of clinical and
pathological features of LCCN in patients with MM, according to a retrospective review
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Introduction
Acute kidney injury (AKI) is a common complication in symptomatic multiple myeloma (MM),  and
light chain cast nephropathy (LCCN) is the most frequent cause.  LCCN is a myeloma-defining event
that results from the precipitation of monoclonal free light chains (FLCs) with Tamm-Horsfall protein
(THP) in distal tubules leading to tubular obstruction, interstitial inflammation, and, eventually,
irreversible interstitial fibrosis and tubular atrophy (IFTA).  Histologically, LCCN is characterized by
intratubular proteinaceous casts by light microscopy, typically showing light chain (LC) restriction by
immunofluorescence.
Controversy exists over the benefits of renal biopsy in patients with renal impairment and MM. The
International Myeloma Working Group (IMWG) has suggested that this procedure is not necessary when
the diagnosis of LCCN is likely (ie, in patients presenting with high serum FLC levels and predominant
LC proteinuria). However, histologic confirmation may be helpful for patients with unrelated confounding
conditions, such as diabetes, or when significant albuminuria exists.  In addition, a study of MM with
LCCN found a significant proportion of patients with coexisting nephropathies, including light chain
deposition disease (LCDD) and light chain (AL) amyloidosis.  The authors also found that the number of
casts and the severity of tubular atrophy were associated with renal outcomes in the subgroup of
hematologic responders.
The introduction of novel agents has increased survival in MM, even among patients with severe renal
impairment.  However, poor renal function may lower drug tolerance and limit treatment options,
particularly high-dose melphalan followed by autologous stem cell transplantation, considered standard
therapy in young patients.  Renal response depends on the achievement of rapid and deep hematologic
response  and is associated with improved overall survival (OS), although not all series have confirmed
this effect.  Because very few studies provided renal pathology data, whether renal histology may
predict renal outcome remains unknown. We conducted a multicenter retrospective cohort study of 178
patients with MM and biopsy-proven LCCN to assess reproducibility of histologic findings and evaluate














Patients were selected from renal biopsy databases from 10 centers after approbation from local
institutional review boards. The databases were queried for histologic diagnoses of LCCN between
February 2000 and January 2018. Inclusion criteria were: (1) established diagnosis of MM according to the
2014 IMWG criteria ; (2) at least one cast with typical appearance according to light microscopy; (3) at
least one cast staining for anti-κ or anti-λ by immunofluorescence or immunohistochemistry; and (4)
sufficient follow-up to assess hematologic response. Research was conducted in accordance with the
Declaration of Helsinki.
Clinical data set
Demographic characteristics, baseline clinical and biological data, antimyeloma therapy, use of plasma
exchange or high cutoff hemodialysis, hematologic response (including FLC reduction after the first
cycle  and best FLC response), best estimated glomerular filtration rate (eGFR) value, and patient
survival data were collected. The presence of precipitating factors for AKI, including infection, use of
nephrotoxic drugs or contrast media, and hypercalcemia, was recorded.
Pathology
Standard processing of renal biopsy specimens for light microscopy and immunofluorescence was
performed, including systematic staining with antibodies to κ and λ LCs. Glass slides were independently
reviewed by 2 pathologists. Sixteen pathologists participated in the scoring. Scoring definitions,
instructions, and scoring sheets were generated and distributed to collect a detailed pathology data set.
Pathology variables were defined as detailed in Table 1 and illustrated in Figure 1. Using all available
slides, a semi-quantitative histologic assessment of glomerular and tubulointerstitial lesions was
performed. On the most representative periodic acid–Schiff or trichrome-stained section, the extent of cast
formation was assessed by calculating the mean and highest number of casts per square millimeter in the
cortex and, separately, in the medulla. The mean number of casts per square millimeter was defined as the
total number of casts divided by the estimated area of cortex or medulla. The highest number of casts was
defined as the highest number of casts in one 20× field, adjusted for 1 mm . The presence of other
monoclonal immunoglobulin–related renal lesions was recorded.
For variables with a divergent categorical score, discrepancies were solved by discussion to generate a
consensus score. For the evaluation of continuous variables, differences between the counts >25% were
reviewed simultaneously. Otherwise, the average of the 2 reviewers was used.
Definitions
Hematologic response was defined according to the IMWG criteria : stringent complete response
(CR), CR, very good partial response (VGPR), partial response, stable disease, and progressive disease.
Because not all patients underwent a bone marrow biopsy, we merged stringent CR, CR, and near CR,
defined as negative serum and urine immunofixation, without bone marrow biopsy examination. IMWG
hematologic response was assessed retrospectively in patients who presented before 2006. When FLCs
were not available, hematologic response was based on serum and urine immunofixation and protein
electrophoresis.
eGFR was calculated by using the Modification of Diet in Renal Disease four-variable formula. AKI stage
was determined according to the Acute Kidney Injury Network (AKIN) criteria, using the preexisting
serum creatinine value,  and, if not available, using the best serum creatinine value during follow-up if
the corresponding eGFR was >60 mL/min/1.73 m , as a reflection of preexisting creatinine.
Renal outcomes included best eGFR value during follow-up, in which individuals who remained dialysis
dependent had their best eGFR set at 10 mL/min/1.73 m . We also recorded those who remained dialysis
dependent. Renal responses were also determined according to the IMWG criteria,  as follows: CR (best
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59 mL/min/1.73 m  best when baseline eGFR <15 mL/min/1.73 m ), and minor response (best eGFR 15-
29 mL/min/1.73 m  or 30-59 mL/min/1.73 m  in those with baseline eGFR <15 or 15-29 mL/min/1.73 m ,
respectively).
For outcome analyses, only individuals who received at least 1 chemotherapy cycle and completed at least
2 months of follow-up were considered.
Statistical analyses
Normally distributed variables are expressed as mean ± standard deviation and compared by using the
Student t test, one-way analysis of variance, or Pearson correlation. Nonparametric variables are expressed
by using median with interquartile range or percentages and compared by using the Mann-Whitney,
Kruskal-Wallis, or Spearman test. Proportions are compared by using the Pearson χ  test. Analyses were
performed by using SPSS software version 11 (IBM SPSS Statistics, IBM Corporation, Armonk, NY) and
R software (version 3.3.2; R Foundation for Statistical Computing, Vienna, Austria).
Agreement assessment was performed between local and central review (V.R.). We used Gwet’s agreement
coefficient (GAC) for dichotomous variables and the intraclass correlation coefficient for ordinal or
continuous variables.  The GAC has been validated in simulation approaches and is more robust
compared with the classic κ score for dichotomous outcomes.  By convention, a GAC or intraclass
correlation coefficient value <0.40 indicates poor interrater reliability; 0.40 to 0.59 is moderate, and ≥0.60
is good.
Correlations between pathology variables were conducted by using the phi, Cramer’s V, or Spearman test,
as appropriate. Given the number of possible comparisons between pathology variables, the Holm-
Bonferroni method was used to minimize the risk of type I error.
To test the associations between clinicopathologic variables and renal outcomes, we categorized
continuous variables into groups, defined according to clinically relevant cutoffs or by tertiles rounded to
the simplest value. Variables associated with best eGFR by univariate analyses were tested for
independence by using a stepwise linear regression. Variables associated with dialysis dependency were
tested by using multivariate Cox proportional hazards regression, and variables associated with renal
response according to IMWG were tested by using a logistic regression grouping complete, partial, and
minor responses together. Hazard ratios and odds ratios (ORs) are reported with 95% confidence intervals
(CIS).
OS according to renal and hematologic responses was compared by using Kaplan-Meier curves. Renal
responses were categorized in groups of <15, 15 to 29, 30 to 44, 45 to 59, and ≥60 mL/min/1.73 m .  A
time-dependent Cox proportional hazards analysis was used to investigate if the best eGFR was associated
with OS independently from hematologic response in which survival before hematologic response was




Demographic and myeloma characteristics, renal presentation, and AKI risk factors at the time of LCCN
diagnosis in the 178 patients are shown in Table 2. Mean age was 66 ± 11 years, and median time between
MM diagnosis and LCCN diagnosis was 2 (0-25) days. Ninety-two percent of biopsy samples were
obtained before first-line therapy and 8% at myeloma relapse. The median serum level of involved FLC
was 5010 (2780-10 504) mg/L, with median bone marrow plasma cell infiltration of 50% (27%-75%) and
a β -microglobulin level of 13 (7-22) mg/L. Baseline mean eGFR was 13 ± 11 mL/min/1.73 m . Eighty-
two percent of patients had AKIN stage 3, and 83 subjects (47%) required hemodialysis at presentation.
Median level of proteinuria was 2.3 (1.2-4.4) g/d, and median albuminuria was 9% (5%-16%). Five
patients (2.8%) experienced renal biopsy complications, including retroperitoneal hematomas (n = 4) and
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Pathology findings
Biopsy findings are detailed in Figure 2. The median number of glomeruli was 11 (8-20). Median
proportion of global and segmental glomerulosclerosis was 9% and 14%, respectively. THP was found in
the Bowman space in 6.2% of cases. Cortical and medullary inflammation, usually mild, was found in
95% and 75% of cases. Acute tubular injury, tubulitis, giant cell reaction around casts, and tubular rupture
were observed in 94%, 82%, 60%, and 62% of cases. Forty-six percent and 52% of patients had moderate
to severe IFTA and arteriosclerosis. The interstitium showed giant cells or THP extravasation in 19% and
32% of cases.
The mean and highest numbers of casts per square millimeter were 3.2 (1.4-6.4) and 7.8 (3.9-12.6) in the
cortex, and 2.2 (0.8-4.5) and 4.1 (2.0-7.8) in the medulla. Only 7 patients had <5 cortical or medullary
casts within a total surface area of 6.1 (4.8-10.2) mm . Eleven patients (6.2%) had associated LCDD, with
nodular glomerulosclerosis and/or thickening of tubular basement membranes and linear LC staining along
basement membranes according to immunofluorescence. Four patients (2.2%) had concomitant AL
amyloidosis, with Congo red–positive deposits showing typical ultrastructural fibrillary organization.
Focal interstitial infiltration by neoplastic plasma cells was found in 3 patients. Other clinically relevant
findings were cryoglobulinemic glomerulonephritis (n = 1), fibrillary glomerulonephritis (n = 1), and
crystalline LC proximal tubulopathy (n = 2).
Intercorrelations between pathology findings are detailed in supplemental Table 1 (available on the Blood
Web site). The highest and mean number of casts per square millimeter were strongly intercorrelated in the
cortex (r = 0.90) and medulla (r = 0.92).
The GAC and intraclass correlation coefficient scores between pathology variables showed good
reproducibility (scores >0.6), except for arteriosclerosis (0.55), giant cell reaction around casts (0.59),
tubular rupture (0.47), and interstitial edema (0.34) (Table 3).
Correlations between baseline eGFR and clinicopathologic findings
Higher age, β -microglobulin, involved FLC level, lactic acid dehydrogenase, and bone marrow plasma
cell infiltration were associated with lower eGFR at diagnosis; higher proteinuria was associated with
slightly higher eGFR (Table 4). Medullary inflammation, giant cell reaction around casts, and higher
number of casts in the cortex or medulla correlated with lower baseline GFR. Similar associations were
found by using the AKIN stage (3 vs other) or hemodialysis at presentation as outcomes (data not shown).
Treatments and outcomes
Five patients did not complete 1 cycle of treatment, and 19 died within 2 months of diagnosis. In the 154
patients available for outcome analysis, median follow-up duration was 22 (11-44) months. Most patients
received bortezomib or immunomodulatory drug–based regimens at first (82%) or at second (100%) line (
Table 5). FLC removal (plasma exchange or high-cutoff dialysis) and high-dose melphalan followed by
autologous stem cell transplantation were performed in 36% and 39% of cases, respectively.
Hematologic response VGPR or better occurred in 69% of patients after a median of 5 (3-8) months (near
CR occurred in 38% of cases and VGPR in 31%) (Table 5). Seventy-three percent had a ≥60% reduction in
involved FLC level after 1 cycle. Median best FLC reduction was 99% (93%-99%), with a median FLC
level of 38 (13-319) mg/L.
The best eGFR value was 43 ± 30 mL/min/1.73 m . It occurred at 5 (0-9) months, when 138 of 154
patients were still being followed up. Among 83 patients who required dialysis at presentation, 64 were
included in the follow-up analyses after excluding early deaths and untreated patients. Seven additional
individuals required dialysis during follow-up. Of these 71 patients, 56% (40 of 71) remained dialysis
dependent. Overall, 26% (40 of 154) of the population remained dialysis dependent at last follow-up.
The overall survival was 37 (9-69) months, and there were 103 deaths that occurred within a median of 13
(3-34) months after LCCN diagnosis. Of the remaining 75 patients, 17 were lost to follow-up (9.6%), and
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Factors associated with renal outcomes
Older age, lower initial eGFR, LCCN diagnosed at myeloma relapse, higher baseline FLC level, and β -
microglobulin levels were strongly associated with a lower eGFR during follow-up (Table 6).
Achievement of hematologic response VGPR or better, ≥60% reduction of the involved FLCs after 1
cycle, and lower involved FLC level during follow-up correlated with a higher follow-up eGFR value. We
found no correlation between the presence of risk factors for AKI at presentation and the best eGFR. Giant
cell reaction around casts, greater IFTA, and associated AL amyloidosis or LCDD were associated with
lower follow-up eGFR. THP extravasation correlated with higher follow-up eGFR (57 ± 35 vs 36 ± 26
mL/min/1.73 m ; P < .001), although these patients had higher baseline eGFR (16 ± 14 vs 12 ± 10
mL/min/1.73 m ; P = .07) and less frequent moderate to severe IFTA (33% vs 55% in patients without
THP extravasation; P = .01). eGFR and dialysis outcomes according to different methods of assessment of
the extent of cast formation are shown in Figure 3. eGFR increased to 32 ± 24 mL/min/1.73 m  in patients
with mean number of casts >5/mm  (44% dialysis dependent) vs 52 ± 33 mL/min/1.73 m  (16% dialysis-
dependent) in those with ≤2 casts/mm . We found similar results when considering only patients who
achieved ≥60% reduction in FLCs after 1 cycle of chemotherapy (n = 103).
Although LCCN occurring at myeloma relapse was not associated with lower baseline eGFR, it was
strongly associated with a lower best eGFR (23 ± 15 vs 44 ± 31 mL/min/1.73 m ; P = .002) and lower
hematologic response rate (30% with VGPR or better compared with 72%; P = .006). Patients who
presented with LCCN at myeloma relapse had a greater proportion of giant cell reaction around casts (40%
vs 17%; P = .03), although they had similar amounts of IFTA and casts.
Variables selected according to univariate analysis were compared in a multivariate model by using a
stepwise method (Table 6). We only considered the best hematologic response, since a 60% reduction in
FLCs after the first cycle and the best FLC level were closely interrelated. Age, β -microglobulin level,
best hematologic response, mean number of cortical casts per square millimeter, and degree of IFTA were
independently associated with best eGFR during follow-up. Findings were identical when considering the
highest instead of the mean number of casts per square millimeter. The interrelations between number of
casts and IFTA with baseline and best follow-up eGFR are illustrated in Figure 4.
Factors associated with dialysis dependency were a lower initial eGFR, presence of any risk factor of AKI,
higher β -microglobulin, the absence of a hematologic response VGPR or better, greater number of casts
per square millimeter, and presence of concomitant amyloidosis or LCDD. A multivariate Cox regression
using these variables identified β -microglobin (hazard ratio, 1.03 per mg/L increase; 95% CI, 1.01-1.04;
P < .001), mean number of cortical casts per square millimeter (hazard ratio, 2.21 per increase in tertile;
95% CI, 1.26-3.90; P = .006), and failure of achieving hematologic response VGPR or better (hazard ratio,
4.38; 95% CI, 1.81-10.57; P = .001) as independently associated with dialysis dependency.
When considering the IMWG renal response criteria, merging complete, partial, and minor responses,
lower β -microglobulin level, absence of any risk factor of AKI, achievement of hematologic response
VGPR or better, lower number of casts per square millimeter, lower severity of arteriolosclerosis, and
absence of amyloidosis or LCDD were associated with a higher probability of renal response by univariate
analysis. In the multivariate model, β -microglobulin (OR, 0.96; 95% CI, 0.93-0.98; P = .003), mean
number of cortical casts per square millimeter (OR, 0.40 per increase in tertile; 95% CI, 0.19-0.87; P =
.02), and achieving VGPR or better (OR, 8.40; 95% CI, 2.41-29.29; P = .001) were independently
associated with renal response.
Impact of first-line treatments on renal outcomes
In the follow-up cohort, we compared the respective effect of first-line chemotherapy with bortezomib,
immunomodulatory drugs, and alkylating or vincristine-based regimens. Although the initial eGFR was
similar (±1 mL/min/1.73 m ), the bortezomib group achieved a significantly higher best eGFR value (46 ±
31 mL/min/1.73 m ) compared with patients who received immunomodulatory drugs (33 ± 25
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lower rate of dialysis dependency (20% vs 40% and 46%, respectively; P = .004). Rates of a hematologic
response VGPR or better were significantly higher in the bortezomib group (78% vs 60% and 29%; P <
.001).
Among patients requiring hemodialysis at presentation, the best eGFR achieved was higher in those who
received extracorporeal removal of FLCs, compared with those who did not (33 ± 27 vs 21 ± 20
mL/min/1.73 m ; P = .046). Moreover, they exhibited a trend for lower dialysis dependency (45% vs 60%)
and higher hematologic response VGPR or better (77% vs 61%) (P = .25 and 0.16, respectively).
Finally, autologous stem cell transplantation was strongly associated with the best eGFR, as expected,
because a preserved eGFR is a prerequisite for such therapy (data not shown).
Factors associated with the number of casts and IFTA
Given that 2 independent pathology findings were associated with the best eGFR during follow-up, we
sought to determine which baseline clinical factors could foretell the number of casts and degree of IFTA.
The number of casts correlated with the degree of bone marrow infiltration, FLC level, and proteinuria.
Patients with ≤2, 2 to 5, and >5 mean cortical casts per square millimeter had baseline FLC levels of 3910
(1605-7970), 4920 (2875-8495), and 6460 (4120-15650) mg/dL, respectively, indicating substantial
overlap. No significant association was found between the degree of chronic tubulointerstitial changes and
eGFR before the diagnosis of LCCN, baseline eGFR, age, comorbidities, previous chemotherapy for MM,
or time interval between the diagnoses of MM and LCCN.
Associations between renal, hematologic response, and OS
OS was strongly associated with the best eGFR value with a hazard ratio of death of 1.6 (1.3-1.9) per
every 15 mL/min/1.73 m  drop in eGFR below 45 mL/min/1.73 m  (P < .001) (Figure 5A). When using
the IMWG criteria, complete, partial, and minor renal responses were associated with a greater OS
compared with no renal response (P < .001). However, there was no statistically significant difference in
OS between types of renal response. Finally, the quality of hematologic response correlated with OS (P <
.001) (Figure 5B).
A multivariate Cox regression analysis using a time-dependent expression of hematologic response found
the best eGFR associated with an independent hazard ratio of death of 1.4 (1.1-1.8) per every 15
mL/min/1.73 m  drop in eGFR below 45 mL/min/1.73 m  (P = .003). By contrast, baseline eGFR was not
associated with increased OS, with a hazard ratio of death of 0.98 (95% CI, 0.96-1.01; P = .15) for every 1
mL/min/1.73 m  increase in initial eGFR. Achieving VGPR or better was associated with a 0.5 (0.3-0.9)
time-dependent hazard of death (P = .01).
Discussion
In this large multicenter retrospective study, renal pathology features in patients with LCCN correlated
with both initial and follow-up renal function. The extent of cast formation and the degree of IFTA were
significantly associated with renal recovery in multivariate analysis, independently to baseline clinical
features and to hematologic response. We also found that achieving a renal response was associated with
higher OS independently of the hematologic response. Importantly, initial clinical assessment was poorly
representative of pathology, underscoring the value of performing a renal biopsy when managing patients
with MM and severe AKI. Although these results are currently insufficient to recommend treatment
adaptation based on renal pathology findings, future interventional studies dedicated to renal outcomes in
LCCN should consider stratification according to the amount of casts and degree of IFTA.
In the previous series that focused on determinants of renal recovery in LCCN, 2 main factors were
identified: the severity of renal impairment and the rapid achievement of a deep and sustained hematologic
response.  Even though deep FLC response is a required condition for renal recovery, it is not
sufficient, and identifying reliable predictors of renal prognosis would help in the prognostication and
management of LCCN. The present analysis confirms previously established factors associated with renal
response: age <65 years, baseline eGFR, involved FLCs, and β -microglobulin level were significantly
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better, or by ≥60% reduction of FLC level after 1 cycle of treatment, or by the lowest FLC level obtained,
correlated with better renal outcome. Sixty-nine percent of patients experienced VGPR or better, a high
response rate probably due to the large use of novel agents as first-line therapy.  Supporting the
importance of a rapid FLC reduction,  we recorded a higher best eGFR in patients requiring
hemodialysis at presentation when treated with extracorporeal removal of FLCs; these patients also
showed a tendency toward better hematologic response. In our study, the maximal renal response
expressed as the best eGFR and the best hematologic response occurred simultaneously at 5 months,
reinforcing the value of the best eGFR as a reliable parameter of renal response.
To date, little information exists on the prognostic value of renal histologic features in LCCN. We
performed an extensive morphologic assessment and applied a robust methodology with all renal biopsy
samples reviewed independently by 2 pathologists, with good inter-reader reproducibility. We found that
the extent of cast formation and, to a lesser extent, IFTA were associated with renal response
independently of baseline clinical characteristics and depth of hematologic response. In pioneering
studies,  only extensive interstitial inflammation and fibrosis correlated with poor renal recovery. In a
study by Johnson et al,  the degree of cast formation was the strongest predictive factor of irreversible
renal failure. However, these series were limited by their small size, the inclusion of diagnoses other than
LCCN, and the absence of assessment of FLC response. In a cohort of 70 patients, Ecotière et al  found
that only in patients who achieved a hematologic response were the number of casts and the extent of
tubular atrophy inversely proportional to the probability of renal response. Interstitial fibrosis was not
significantly associated with renal outcome, possibly due to insufficient sample size.
IFTA reflect the chronic damage and are crucial determinants of renal outcome in most renal diseases.
In the transition of AKI to CKD, recent observations showed that proximal tubule reabsorption of
monoclonal FLCs promotes a pro-inflammatory/fibrotic state that develops early on with the kidney
injury.  THP released in interstitium has been shown to trigger inflammation by activating dendritic cells
through Toll-like receptor 4 signaling  and by promoting secretion of interleukin-1β by the NRLP3
inflammasome.  We found that THP extravasation was associated with a higher follow-up eGFR,
although it also correlated with higher initial eGFR and milder IFTA. These data suggest that uromodulin
accumulation in the interstitium may reflect an early consequence of tubule obstruction by casts.
We assessed the extent of cast formation by estimating the highest and the mean number of casts per
square millimeter, separately in the cortex and the medulla. The number of casts seemed to reflect the
disease burden, as patients with numerous casts exhibited higher bone marrow infiltration and higher FLC
levels at presentation. However, the extent of cast formation could not be predicted by baseline level of the
involved FLCs. Indeed, casts not only reflect the amount of monoclonal LC that reach the distal tubule
lumen but also the affinity of LC for THP, which is determined by the structure of the LC hypervariable
domain (complementarity-determining region 3) that binds to a specific 9 amino-acid region of THP.  In
the current study, both the mean and highest number of cortical casts per square millimeter were
independently associated with renal outcomes. Therefore, in routine clinical practice, we propose to report
only the highest number of casts per square millimeter in the cortex, using simple cutoffs of <5, 5 to 10,
and >10 casts/mm .
Renal recovery has been associated with improved OS in patients with LCCN.  However, recent
studies have questioned the validity of this relation in the era of novel antimyeloma agents.  These
studies were smaller, the definition of renal outcomes varied, initial eGFRs were higher, and the proportion
with LCCN was unknown. de Vries et al  studied 131 patients newly diagnosed with MM and renal
impairment and found that renal recovery was not associated with a better OS, even in patients with severe
renal impairment. However, only 52 patients had an eGFR <30 mL/min/1.73 m , which contrasts with the
initial eGFR of 13 mL/min/1.73 m  in our study. The MM-013 trial also reported similar OS and
progression-free survival in patients with and without renal recovery, although nonrenal responders
showed a trend for shorter OS. In this study, patients had relapsed/refractory MM, most had chronic renal


















06/07/2020 Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243151/?report=printable 10/26
Our data support the predictive value of renal improvement for OS, independently of the hematologic
response, although we were not able to ascertain the rapidity of renal response and hence could not use a
time-dependent expression of final eGFR. However, because improvement in renal function usually occurs
within the first 6 months, a lead-time bias is unlikely.  Our multivariate model indicates that the best
eGFR during follow-up is more relevant than the presenting one. Figure 5A shows that achievement of
renal response according to IMWG criteria was associated with higher OS. However, differences between
complete, partial, and minor responses were not clear, as opposed to a strong dose-dependent effect of the
best eGFR obtained. Because pathologic findings independently correlate with renal outcome, this
scenario underscores the clinical value of renal biopsy as a predictive tool for renal recovery and OS.
Renal biopsy is also useful for the diagnosis of coexisting monoclonal immunoglobulin–related renal
diseases, present in 12% of LCCN cases in our series, including AL amyloidosis and LCDD in 2.2% and
6.2% of patients, respectively. The association of LCCN with other monoclonal immunoglobulin–related
renal diseases was observed in 16% of cases reported by Ecotière et al  and 14% of those reported by Nasr
et al.  These patients require careful clinical assessment for extrarenal involvement that requires specific
management. Furthermore, the addition of different renal lesions seems to influence renal prognosis in
patients with MM. Zand et al  reported that patients with pure LCDD have better renal prognosis than
those with both LCDD and LCCN. In our study, patients with LCCN and coexisting amyloidosis or LCDD
achieved lower eGFR during follow-up, compared with those with pure LCCN.
The methodology used in this study deserves further comments. We considered all individuals at onset, but
for follow-up assessment, we excluded those in whom no improvement in renal function could be expected
(ie, who died prematurely, or did not receive a minimum of 1 cycle of chemotherapy and 2 months of
follow-up). To eliminate the effect of ongoing FLC injury on top of the initial biopsy findings, we also
considered only those who achieved a ≥60% drop in FLC levels after 1 cycle  and found the same
findings according to univariate analysis. Inevitably, selecting these patients resulted in increased final best
eGFR. This approach will have to be taken into account when comparing data from other cohorts.
Certain limitations must be addressed. In this retrospective study, antimyeloma regimens varied over time.
It is possible that future treatments will lead to a greater renal recovery and modify the independent
predictors identified here. The choice of the main predictive outcome, best eGFR, can occur at various
times, and results may be different when considering eGFR at 1, 3, or 6 months. Nevertheless, this
outcome proved superior to renal response according to the IMWG criteria, and other outcomes such as
dialysis dependency identified similar predictors. Also, the decision to perform a renal biopsy in patients
with AKI may have influenced the results of this study. Because it is not routinely performed in most
centers, this overselection may have excluded individuals with poor prognosis or less rapid or severe AKI.
In conclusion, this study shows the importance of renal biopsy findings in predicting the renal response in
LCCN. As in previous studies,  our findings also confirm the safety of the renal biopsy in patients
with MM, similar to that of other populations.
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The online version of this article contains a data supplement.
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Table 1.
Pathology definitions for scoring
Evaluation based on all available slides.
Evaluation based on the most representative periodic acid–Schiff or trichrome-stained slide.
LCCN: Histological diagnosis of LCCN was defined as follows: (1) at least one cast with typical appearance of
LC cast by light microscopy; and (2) at least one cast staining for anti-κ or anti-λ conjugate by
immunofluorescence or immunohistochemistry
LC cast: Tubular cast that meets ≥2 of these 3 criteria: (1) periodic acid–Schiff negative and/or
polychromatophilic on trichrome and/or eosinophilic on hematoxylin-eosin and/or Congo red positive; (2)
fractured and/or sharp edged and/or brittle and/or crystalline appearance; or (3) cellular and/or giant cell reaction
around the cast
Glomerular definitions
 THP in the Bowman’s space: Identification of THP in the Bowman’s space
Tubulointerstitial definitions
 Tubular atrophy and interstitial fibrosis: Thickened tubular basement membranes, flattened epithelial cells,
expanded interstitium with fibrosis in the cortex. <10% (0), 10%-24% (1), 25%-50% (2), >50% (3)
 Interstitial inflammation: Increased interstitial leukocytes in the cortex. None (0), focal <50% of the cortex
(1), diffuse ≥50% (2) assessed for the cortex, and separately for the medulla
 Acute tubular injury: Cortical tubular epithelial flattening and loss of brush border, or necrosis of tubular
epithelial cells, denudation of the tubular basement membranes
 Interstitial edema: Expansion of the interstitium by edema
 Tubulitis: Infiltrating mononuclear cells in the tubular epithelium of nonatrophic and atrophic tubule
 THP extravasation: Identification of THP extravasation into the interstitium
 Giant cell reaction around casts: Identification of at least one multinucleated histiocyte surrounding an LC
cast
 Tubular rupture: Interruption in the tubular basement membrane secondary to dilatation, to the presence of an
LC cast or inflammation
 Interstitial giant cell reaction: Identification of a least one multinucleated histiocyte in the interstitium
 Extent of cast formation definitions assessed for the cortex, and separately for the medulla
 Estimated area (square millimeter): Total number of 20× fields of cortex/medulla multiplied by the area of one
20× field in square millimeter
 Mean number of casts per square millimeter: Total number of casts in the cortex/medulla divided by the
estimated area of cortex/medulla
 Highest number of casts per square millimeter: Highest number of LC casts in one 20× field divided by the
area of one 20× field in square millimeter
Vascular definitions
 Arteriosclerosis: Thickening of the intima with fibrosis or duplication of the elastic lamina. Absent (0),







06/07/2020 Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243151/?report=printable 17/26
Figure 1.
Pathology illustrations. Intraluminal LC casts with the typical appearance. By light microscopy: (A) sharp-edged
periodic acid–Schiff negative casts surrounded by a cellular reaction (magnification ×600), (B) fractured cast on trichrome
stain (magnification ×600), (D) eosinophilic granular casts on hematoxylin and eosin stain (magnification ×400), and (E)
multinucleated giant cell reaction around a fractured cast (magnification ×400). By immunofluorescence: (C) positive
staining with anti-κ (magnification ×100) and (F) negative staining with anti-λ (magnification ×100). Images of pathology
features that were recorded: (G) extensive interstitial fibrosis and tubular atrophy with scarce mononuclear interstitial
inflammation (periodic acid–Schiff, magnification ×100), (H) tubular rupture with the interruption of the tubular basement
membrane (arrow) (Jones methenamine silver, magnification ×400), (I) interstitial giant cells (arrow) (periodic acid–
Schiff, magnification ×400), (J) interstitial inflammation with tubulitis (arrow) (periodic acid–Schiff, magnification
×600), (K) THP extravasation into the interstitium (asterisk) (periodic acid–Schiff, magnification ×200), and (L) THP
protein in the Bowman’s space (asterisks) (periodic acid–Schiff, magnification ×400).
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Table 2.
Clinical characteristics at time of diagnosis of LCCN
Open in a separate window
Missing data were as follows: size of monoclonal spike, 15%; FLC, 5%; % bone marrow plasma cells, 18%; lactic
acid dehydrogenase (LDH), 21%; β -microglobulin, 33%; lytic lesions, 11%; eGFR before LCCN, 29%.
AA, African American; Ig, immunoglobulin.
Characteristic Patients (n = 178)
Demographic characteristics
 Age, y 66 ± 11
 Ethnicity, % white, AA, Asian, Middle Eastern, other 90, 6, 1, 1, 2
 Female sex, % 45
Medical history
 Hypertension, % 40
 Congestive heart failure, % 2.3
 Vascular disease, % 16
 Diabetes, % 14
Myeloma characteristics
 Prior chemotherapy for myeloma, % 7.3






 Size of monoclonal spike, g/L 12 (3-32)
 FLC level, mg/L 5010 (2780-10 504)
 κ/λ, % 47/53
 Bone marrow plasma cells % 50 (27-75)
 Hemoglobin, g/L 92 ± 17
 LDH, U/L 270 ± 145
 β -microglobulin, mg/L 13 (7-22)
 Presence of lytic bone lesions, % 63
Renal characteristics
 eGFR before LCCN, mL/min/1.73 m 76 ± 27
 eGFR, mL/min/1.73m 13 ± 11
 AKIN stage (0, 1, 2, 3) 1, 5, 12, 82
 Dialysis dependence, % 47
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Figure 2.
Pathology findings. There was no cortex in 3 biopsy specimens and no medulla in 67 (38%), where no highest or mean
number of casts could be determined.
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Table 3.
Pathology agreement between reviewers
Pathology findings ICC GAC
Ratio of globally sclerosed glomeruli 0.84
Ratio of glomeruli with segmental sclerosis 0.42
Interstitial fibrosis and tubular atrophy, 0-1-2-3 0.61
Cortical interstitial inflammation, 0-1-2 0.60
Medullary interstitial inflammation, 0-1-2 0.73
THP in Bowman’s space, yes/no 0.92
Acute tubular injury, yes/no 0.72
Interstitial edema, yes/no 0.34
Tubulitis, yes/no 0.61
Giant cell reaction around casts, yes/no 0.59
Tubular rupture, yes/no 0.47
THP extravasation, yes/no 0.60
Interstitial giant cell reaction, yes/no 0.80
Highest number of cortical cast/mm 0.73
Mean no. of cortical cast/mm 0.75
Highest no. of medullary cast/mm 0.90
Mean no. of medullary cast/mm 0.92
Arteriolosclerosis, 0-1-2-3 0.66
Arteriosclerosis, 0-1-2-3 0.55
A GAC score of 0.59 corresponds to an absolute agreement of 79% between the 2 pathologists.
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Table 4.
Clinicopathological correlations with eGFR at LCCN diagnosis
Open in a separate window




 ≤60 16 ± 15 .04 (≤60 compared with >60)
 60-70 12 ± 9
 >70 11 ± 9
LCCN at myeloma relapse
 Absent 13 ± 12 .73
 Present 15 ± 9
Proteinuria, g/d
 ≤2.0 12 ± 9 .03 (>4 g/d compared with ≤4
g/d) 2.1-4.0 12 ± 9
 >4.0 17 ± 16
Free light chains, mg/L
 ≤3500 15 ± 11 .04 (trend test)
 3501-7000 14 ± 14
 >7000 11 ± 10
Lactic acid dehydrogenase, U/L
 ≤200 16 ± 15 .03 (trend test)
 201-400 12 ± 9
 >400 11 ± 9
β -microglobulin, mg/L
 ≤10.0 22 ± 17 <.001 (trend test)
 10.1-20.0 12 ± 8
 >20.0 7 ± 6
Bone marrow plasma cells, %
 ≤33% 16 ± 11 .05
 34-66 13 ± 14
 >66% 11 ± 8
Medulla interstitial inflammation, 0 vs
1-2+
 0 20 ± 20 .04
1 to ≥2 12 ± 9
2
2
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Table 5.
Treatment, hematology, and nephrology outcomes in treated individuals (n = 154)
Duration of follow-up, month 22 (11-44)
First-line chemotherapy, n (%)
 Bortezomib-based therapy 93 (60)
 IMiD-based therapy 15 (10)
 Combination bortezomib and IMiDs 19 (12)
 Alkylating-based (without bortezomib or IMiDs) 9 (5.8)
 Vincristine-doxorubicin-dexamethasone 13 (8.4)
 Dexamethasone only 5 (3.2)
Plasma exchange or high-cutoff hemodialysis 36
Second-line chemotherapy, n (%)
 None 79 (51)
 Proteasome inhibitors 26 (17)
 IMiD-based therapy 34 (22)
 Combination proteasome inhibitors and IMiDs 15 (9.7)
Autologous stem cell transplantation 39
Hematologic response, %
 Near CR or better 38
 Very good partial response 31
 Partial response 22
 Stable disease or worse 9
Light chain response
 60% reduction in FLCs after the first cycle, % 73
 FLC ≤ 500 mg/L, % 82
 Best serum FLC level, mg/L 38 (13-319)
 Best FLC reduction, % 99 (93-99)
Renal response
 Best eGFR, mL/min/1.73m 43 ± 30
 Dialysis dependency, % 26%
 IMWG renal response criteria, %
 Complete, partial, minor, none 28, 21, 21, 30
Open in a separate window
Cohort of subjects with at least 2 months’ follow-up and 1 complete chemotherapy cycle were included. Missing data
were as follows: best hematologic remission status (3%), best serum FLC level (13%), best FLC reduction (15%),
>60% reduction in serum FLC level after 1 initial cycle of chemotherapy (18%), and AKIN stage improvement
(16%).
IMiD, immunomodulatory drug.




06/07/2020 Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243151/?report=printable 23/26
Table 6.
Univariate and multivariate correlations with the best eGFR obtained during follow-up
Open in a separate window
Patients with a minimum 2 months’ follow-up and one cycle of treatment were included (n = 154). We included all
the variables associated by univariate analysis in the multivariate model except for “60% reduction in serum FLC
level after the first cycle” and “best FLC” because they are closely interrelated by definition to “best hematologic
response” (*). We also excluded the “mean number of medullary casts” since the medulla was absent in 40% (†).
NR, no response; PR, partial response.
LCCN at myeloma relapse No: 44 ± 31 .002 —
Yes: 23 ± 15
Presenting eGFR, mL/min/1.73 m ≥30: 65 ± 36 <.001 —
15-29: 60 ± 30
<15: 36 ± 26
Baseline serum FLC level, mg/L ≤3500: 48 ± 39 .03 —
3501-7000: 41 ± 34
>7000: 35 ± 28
β -microglobulin, mg/L <10: 57 ± 36 <.001 −0.365 <.001
10-20: 50 ± 25
>20: 25 ± 21
60% reduction in serum FLC level
after the first cycle
Present: 50 ± 29 .001 *
Absent: 31 ± 31
Best hematologic response VGPR or better: 49 ±
30
<.001 0.21 (VGPR or better vs
PR or worse)
.01
PR: 38 ± 30
Stable disease or
worse: 22 ± 20
Best serum FLC level, mg/L ≤25: 58 ± 31 <.001 *
26-500: 42 ± 30
>500: 25 ± 19
Interstitial fibrosis or tubular atrophy 0 to ≥1: 48 ± 32 .01 −0.20 .02
2 to ≥3: 36 ± 26
THP extravasation Present: 57 ± 35 <.001 —
Absent: 36 ± 26
Giant cell reaction around casts Present: 38 ± 28 .02 —
Absent:50 ± 33
Cortex: mean no. of casts/mm ≤2: 52 ± 33 <.001 −0.23 .008
2-5: 42 ± 30
>5: 32 ± 24
Medulla: mean no. of casts/mm ≤1.5: 56 ± 33 <.001 †
1.5-3.0: 41 ± 27
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Figure 3.
Renal outcomes according to mean and highest number of casts in the cortex.
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Figure 4.
Interrelation between independent pathology findings with the initial and best follow-up eGFR.
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Figure 5.
OS according to the renal and hematologic responses. (A) Renal response, (B) hematologic response. nCR, near CR;
PR, partial response.
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